Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 8,785 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 8,785 shares of Stoke Therapeutics stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $31.29, for a total value of $274,882.65. Following the transaction, the general counsel directly owned 15,809 shares in the company, valued at $494,663.61. The trade was a 35.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jonathan Allan also recently made the following trade(s):

• On Thursday, December 4th, Jonathan Allan sold 1,018 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total transaction of $31,425.66.
• On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $70,249.80.
• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total value of $250,700.00.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $30.87 on Friday. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of 46.07 and a beta of 1.14. The stock’s 50-day moving average is $29.03 and its 200 day moving average is $19.83. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The company had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. On average, sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the company. Canaccord Genuity Group boosted their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. Needham & Company LLC lifted their price target on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Finally, Wedbush boosted their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $31.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in Stoke Therapeutics in the 1st quarter worth $267,000. US Bancorp DE increased its position in shares of Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Stoke Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after purchasing an additional 53,004 shares during the last quarter. Invesco Ltd. raised its position in Stoke Therapeutics by 117.0% in the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock worth $174,000 after buying an additional 14,118 shares during the last quarter. Finally, Nuveen LLC bought a new position in Stoke Therapeutics during the first quarter valued at approximately $719,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.